{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:41:11Z","timestamp":1787733671221,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06474-z","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:34:55Z","timestamp":1750912495000},"page":"3875-3879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Alessio Maria Edoardo","family":"Maraglino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sammassimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Pastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"1","key":"6474_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01168-x","volume":"24","author":"T Intermesoli","year":"2022","unstructured":"Intermesoli T, Weber A, Leoncin M et al (2022) Lymphoblastic lymphoma: a concise review. Curr Oncol Rep 24(1):1\u201312","journal-title":"Curr Oncol Rep"},{"issue":"25","key":"6474_CR2","first-page":"3019","volume":"141","author":"SJ Si Lim","year":"2023","unstructured":"Si Lim SJ, Ford JB, Hermiston ML (2023) How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood 141(25):3019\u20133030","journal-title":"Blood"},{"issue":"16","key":"6474_CR3","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","volume":"7","author":"R Bassan","year":"2023","unstructured":"Bassan R, Chiaretti S, Della Starza I et al (2023) Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv 7(16):4448\u20134461","journal-title":"Blood Adv"},{"issue":"1","key":"6474_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT (2016) T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2016(1):580\u2013588","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"6474_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2021.279851","volume":"107","author":"M Cerrano","year":"2022","unstructured":"Cerrano M, Bonifacio M, Olivi M et al (2022) Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational campus ALL study. Haematologica 107(4):996\u2013999","journal-title":"Haematologica"},{"issue":"21","key":"6474_CR6","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT et al (2024) Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood Vol 144(21):2237\u20132247","journal-title":"Blood Vol"},{"issue":"19","key":"6474_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","volume":"40","author":"DT Teachey","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL et al (2022) Children\u2019s oncology group trial AALL1231: A phase III clinical trial testing bortezomib in newly diagnosed T-Cell acute lymphoblastic leukemia and lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol Vol 40(19):2106\u20132118","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol Vol"},{"issue":"8","key":"6474_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/leu.2011.84","volume":"25","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Kuster SP, Hunger SP et al (2011) Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leuk Vol 25(8):1232\u20131238","journal-title":"Leuk Vol"},{"issue":"9","key":"6474_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY et al (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood Vol 131(9):995\u2013999","journal-title":"Blood Vol"},{"issue":"8","key":"6474_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New Engl J Med Vol 375(8):754\u2013766","journal-title":"New Engl J Med Vol"},{"key":"6474_CR11","doi-asserted-by":"crossref","first-page":"P109","DOI":"10.3324\/haematol.2014.105320","volume":"99","author":"P Doshi","year":"2014","unstructured":"Doshi P, Sasser AK, Axel A et al (2014) Daratumumab treatment alone or in combination with vincristine results in the Inhibition of tumor growth and long term survival in preclinical models of acute lymphocytic leukemia. Haematologica 99:P109","journal-title":"Haematologica"},{"key":"6474_CR12","doi-asserted-by":"crossref","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M et al (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 7(2): 311\u2013321","DOI":"10.1080\/19420862.2015.1007813"},{"issue":"2","key":"6474_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"186","author":"TM Horton","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X et al (2019) Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the children\u2019s oncology group. Br J Haematol Vol 186(2):274\u2013285","journal-title":"Br J Haematol Vol"},{"key":"6474_CR14","doi-asserted-by":"crossref","unstructured":"Koyama D, Kikuchi J, Hiraoka N et al (2014) Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28(6): 1216\u20131226","DOI":"10.1038\/leu.2013.366"},{"issue":"8","key":"6474_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver L, Ferrando A (2016) The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer 16(8):494\u2013507","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6474_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nm1524","volume":"13","author":"T Vilimas","year":"2007","unstructured":"Vilimas T, Mascarenhas J, Palomero T et al (2007) Targeting the NF-kappaB signaling pathway in Notch1-Induced T-Cell leukemia. Nat Med 13(1):70\u201377","journal-title":"Nat Med"},{"issue":"4","key":"6474_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11899-024-00735-w","volume":"19","author":"H Pourhassan","year":"2024","unstructured":"Pourhassan H, Murphy L, Aldoss I (2024) Glucocorticoid therapy in acute lymphoblastic leukemia: navigating Short-Term and Long-Term effects and optimal regimen selection. Curr Hematol Malig Rep 19(4):175\u2013185","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"6474_CR18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00277-024-06121-z","volume":"104","author":"L Shakeel","year":"2025","unstructured":"Shakeel L, Khaliq N, Shaukat A et al (2025) The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Ann Hematol 104(2):1139\u20131155","journal-title":"Ann Hematol"},{"issue":"1","key":"6474_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/clinpract14010022","volume":"14","author":"D Raposo Puglia","year":"2024","unstructured":"Raposo Puglia D, Raposo Puglia J\u00c1, Garc\u00eda-Cabrera E et al (2024) Risk factors and environmental preventive actions for aspergillosis in patients with hematological malignancies. Clin Pract 14(1):280\u2013292","journal-title":"Clin Pract"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06474-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:47:40Z","timestamp":1757198860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06474-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6474"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06474-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to publish"}},{"value":"written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}